Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026Score 7/30122% above fair value
$41.47+1.50 (+3.75%)
Close on Oct 29, 2026Market cap $48.32BP/E 69.1Yield –
Earnings
Teva Pharmaceutical Industries's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$4.14B
-0.8% on a year earlier
Non-GAAP diluted EPS, Q2 FY2026
$0.02
$0.66 a year earlier
Latest guidance
Raised
Jul 29, 2026 · 8 items
Quarterly results
Revenue and earnings per share from each of Teva Pharmaceutical Industries's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | $4.14B | -0.8% | -$0.49 | $0.02 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026before the open | $3.98B | +2.1% | $0.31 | $0.53 | Release |
| Q4 FY2025ended Dec 31, 2025 | Jan 12, 2026before the open | – | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | $4.50B | +3.9% | $0.37 | $0.78 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025before the open | $4.18B | +0.3% | $0.24 | $0.66 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $3.90B | +2.1% | $0.18 | $0.52 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 29, 2025before the open | $4.20B | -5.8% | -$0.19 | $0.71 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024before the open | $4.33B | +12.5% | -$0.39 | $0.69 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024before the open | $4.16B | +7.4% | -$0.75 | $0.61 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $3.82B | +3.2% | -$0.12 | $0.48 | Release |
| Q4 FY2023ended Dec 31, 2023 | Jan 31, 2024before the open | $4.46B | +14.8% | $0.41 | $1.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023before the open | $3.85B | +7.1% | $0.07 | $0.60 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023before the open | $3.88B | +2.4% | -$0.77 | $0.56 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | $3.70B | +1.1% | -$0.18 | $0.40 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 8, 2023before the open | $3.88B | -5.3% | -$1.10 | $0.71 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $3.60B | -7.5% | $0.05 | $0.59 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 26, 2022after the close | $3.79B | – | -$0.21 | $0.68 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022before the open | $3.66B | – | -$0.86 | $0.55 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 9, 2022before the open | $4.10B | – | -$0.14 | $0.77 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021before the open | $3.89B | – | $0.26 | $0.59 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 10, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Teva Pharmaceutical Industries's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenues | FY2026 | $16.50B – $16.85B | $16.40B – $16.80B | Raised | Jul 29, 2026 |
| Non-GAAP operating incomenon-GAAP | FY2026 | $3.80B – $4.00B | $3.80B – $4.00B | Reaffirmed | Jul 29, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $4.23B – $4.53B | $4.23B – $4.53B | Reaffirmed | Jul 29, 2026 |
| Non-GAAP diluted EPSnon-GAAP | FY2026 | $1.91 – $2.11 | $1.91 – $2.11 | Reaffirmed | Jul 29, 2026 |
| Free cash flow | FY2026 | $2.00B – $2.40B | – | New | Jul 29, 2026 |
| Free cash flownon-GAAP | FY2026 | $2.00B – $2.40B | – | New | Apr 29, 2026 |
| CAPEX | FY2026 | $500.00M | – | New | Jul 29, 2026 |
| annual non-GAAP tax ratenon-GAAP | FY2026 | 20% – 23% | – | New | Jul 29, 2026 |
| Finance Expenses* | FY2026 | $800.00M | – | New | Jul 29, 2026 |
| non-GAAP operating income marginnon-GAAP | FY2027 | 30% | – | New | Apr 29, 2026 |
| operating profit margin | FY2027 | 30% | – | New | Jul 30, 2025 |
| operating profit marginnon-GAAP | FY2027 | 30% | – | New | May 7, 2025 |
Guidance history
Every forecast Teva Pharmaceutical Industries put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Jul 29, 2026 | CAPEX | FY2026 | $500.00M | New |
| Jul 29, 2026 | Adjusted EBITDA | FY2026 | $4.23B – $4.53B | Reaffirmed |
| Jul 29, 2026 | Non-GAAP diluted EPS | FY2026 | $1.91 – $2.11 | Reaffirmed |
| Jul 29, 2026 | Free cash flow | FY2026 | $2.00B – $2.40B | New |
| Jul 29, 2026 | Non-GAAP operating income | FY2026 | $3.80B – $4.00B | Reaffirmed |
| Jul 29, 2026 | annual non-GAAP tax rate | FY2026 | 20% – 23% | New |
| Jul 29, 2026 | Finance Expenses* | FY2026 | $800.00M | New |
| Jul 29, 2026 | Revenues | FY2026 | $16.50B – $16.85B | Raised |
| Apr 29, 2026 | Adjusted EBITDA | FY2026 | $4.23B – $4.53B | New |
| Apr 29, 2026 | Non-GAAP diluted EPS | FY2026 | $1.91 – $2.11 | New |
| Apr 29, 2026 | Free cash flow | FY2026 | $2.00B – $2.40B | New |
| Apr 29, 2026 | Non-GAAP operating income | FY2026 | $3.80B – $4.00B | New |
| Apr 29, 2026 | non-GAAP operating income margin | FY2027 | 30% | New |
| Apr 29, 2026 | Revenues | FY2026 | $16.40B – $16.80B | New |
| Nov 5, 2025 | Adjusted EBITDA | FY2025 | $4.80B – $5.00B | Raised |
| Nov 5, 2025 | Non‐GAAP diluted EPS | FY2025 | $2.55 – $2.65 | Raised |
| Nov 5, 2025 | Free cash flow | FY2025 | $1.60B – $1.90B | New |
| Nov 5, 2025 | Non‐GAAP operating income | FY2025 | $4.40B – $4.60B | Raised |
| Nov 5, 2025 | Tax Rate | FY2025 | 15% – 18% | Reaffirmed |
| Nov 5, 2025 | Revenues | FY2025 | $16.80B – $17.00B | Raised |
| Nov 5, 2025 | AUSTEDO | FY2025 | $2.05B – $2.15B | Lowered |
| Nov 5, 2025 | AJOVY | FY2025 | $630.00M – $640.00M | Lowered |
| Nov 5, 2025 | UZEDY | FY2025 | $190.00M – $200.00M | Lowered |
| Jul 30, 2025 | CAPEX | FY2025 | $500.00M | New |
| Jul 30, 2025 | Adjusted EBITDA | FY2025 | $4.70B – $5.00B | New |
| Jul 30, 2025 | Non‐GAAP diluted EPS | FY2025 | $2.50 – $2.65 | New |
| Jul 30, 2025 | Free cash flow | FY2025 | $1.60B – $1.90B | New |
| Jul 30, 2025 | Non‐GAAP operating income | FY2025 | $4.30B – $4.60B | New |
| Jul 30, 2025 | operating profit margin | FY2027 | 30% | New |
| Jul 30, 2025 | Finance Expenses | FY2025 | $900.00M | New |
| Jul 30, 2025 | annual non-GAAP tax rate | FY2025 | 15% – 18% | New |
| Jul 30, 2025 | AUSTEDO ($m) | FY2025 | $2.00B – $2.05B | Lowered |
| Jul 30, 2025 | AJOVY ($m) | FY2025 | $630.00M – $640.00M | Lowered |
| Jul 30, 2025 | UZEDY ($m) | FY2025 | $190.00M – $200.00M | Lowered |
| Jul 30, 2025 | COPAXONE ($m) | FY2025 | $370.00M | Raised |
| Jul 30, 2025 | Revenues | FY2025 | $16.80B – $17.20B | New |
| May 7, 2025 | CAPEX* | FY2025 | $500.00M | Reaffirmed |
| May 7, 2025 | Adjusted EBITDA | FY2025 | $4.70B – $5.00B | Raised |
| May 7, 2025 | Non‐GAAP diluted EPS | FY2025 | $2.45 – $2.65 | Raised |
| May 7, 2025 | Free cash flow | FY2025 | $1.60B – $1.90B | Reaffirmed |
| May 7, 2025 | Non‐GAAP operating income | FY2025 | $4.30B – $4.60B | Raised |
| May 7, 2025 | operating profit margin | FY2027 | 30% | New |
| May 7, 2025 | annual non-GAAP tax rate | FY2025 | 15% – 18% | Reaffirmed |
| May 7, 2025 | Finance Expenses | FY2025 | $900.00M | Reaffirmed |
| May 7, 2025 | AUSTEDO revenue | FY2025 | $1.95B – $2.05B | Raised |
| May 7, 2025 | AJOVY revenue | FY2025 | $600.00M | Lowered |
| May 7, 2025 | Revenues | FY2025 | $16.80B – $17.20B | Raised |
| Jan 29, 2025 | CAPEX | FY2025 | $500.00M | New |
| Jan 29, 2025 | Adjusted EBITDA | FY2025 | $4.50B – $5.00B | New |
| Jan 29, 2025 | Non-GAAP diluted EPS | FY2025 | $2.35 – $2.65 | New |
| Jan 29, 2025 | Free cash flow | FY2025 | $1.60B – $1.90B | New |
| Jan 29, 2025 | Non-GAAP operating income | FY2025 | $4.10B – $4.60B | New |
| Jan 29, 2025 | Tax Rate | FY2025 | 15% – 18% | New |
| Jan 29, 2025 | Finance Expenses | FY2025 | $900.00M | New |
| Jan 29, 2025 | Revenues | FY2025 | $16.80B – $17.40B | New |
| Jan 29, 2025 | AUSTEDO | FY2025 | $1.90B – $2.05B | Lowered |
| Jan 29, 2025 | AJOVY | FY2025 | $600.00M | Lowered |
| Jan 29, 2025 | UZEDY | FY2025 | $160.00M | Lowered |
| Jan 29, 2025 | COPAXONE | FY2025 | $370.00M | Raised |
| Nov 6, 2024 | CAPEX* | FY2024 | $500.00M | Reaffirmed |
| Nov 6, 2024 | Adjusted EBITDA | FY2024 | $4.70B – $5.00B | Raised |
| Nov 6, 2024 | Non-GAAP diluted EPS | FY2024 | $2.40 – $2.50 | Raised |
| Nov 6, 2024 | Free Cash Flow** | FY2024 | $1.70B – $2.00B | Reaffirmed |
| Nov 6, 2024 | Operating income | FY2024 | $4.20B – $4.50B | Raised |
| Nov 6, 2024 | Tax Rate | FY2024 | 14% – 17% | Reaffirmed |
| Nov 6, 2024 | Finance Expenses ($m) | FY2024 | $1.00B | Reaffirmed |
| Nov 6, 2024 | Revenues* | FY2024 | $16.10B – $16.50B | Raised |
| Nov 6, 2024 | UZEDY ($m)* | FY2024 | $100.00M | Lowered |
| Nov 6, 2024 | COPAXONE ($m)* | FY2024 | $500.00M | Raised |
| Nov 6, 2024 | AJOVY ($m)* | FY2024 | $500.00M | Lowered |
| Jul 31, 2024 | CAPEX | FY2024 | $500.00M | New |
| Jul 31, 2024 | Adjusted EBITDA | FY2024 | $4.60B – $5.00B | Raised |
| Jul 31, 2024 | Non-GAAP diluted EPS | FY2024 | $2.30 – $2.50 | Raised |
| Jul 31, 2024 | Free Cash Flow | FY2024 | $1.70B – $2.00B | Reaffirmed |
| Jul 31, 2024 | Operating Income | FY2024 | $4.10B – $4.50B | Raised |
| Jul 31, 2024 | Finance Expenses | FY2024 | $1.00B | New |
| Jul 31, 2024 | AJOVY | FY2024 | $500.00M | Lowered |
| Jul 31, 2024 | Tax Rate | FY2024 | 14% – 17% | Reaffirmed |
| Jul 31, 2024 | AUSTEDO revenues | FY2024 | $1.60B | New |
| Jul 31, 2024 | UZEDY | FY2024 | $80.00M | Lowered |
| Jul 31, 2024 | COPAXONE | FY2024 | $450.00M | Raised |
| Jul 31, 2024 | Revenues | FY2024 | $16.00B – $16.40B | Raised |
| May 8, 2024 | Adjusted EBITDA | FY2024 | $4.50B – $5.00B | Reaffirmed |
| May 8, 2024 | Non-GAAP diluted EPS | FY2024 | $2.20 – $2.50 | Reaffirmed |
| May 8, 2024 | Free cash flow | FY2024 | $1.70B – $2.00B | Reaffirmed |
| May 8, 2024 | annual non-GAAP tax rate | FY2024 | 14% – 17% | New |
| May 8, 2024 | Revenues | FY2024 | $15.70B – $16.30B | New |
| Jan 31, 2024 | Adjusted EBITDA | FY2024 | $4.50B – $5.00B | New |
| Jan 31, 2024 | Non-GAAP diluted EPS | FY2024 | $2.20 – $2.50 | New |
| Jan 31, 2024 | Free cash flow | FY2024 | $1.70B – $2.00B | New |
| Jan 31, 2024 | Non-GAAP operating income | FY2024 | $4.00B – $4.50B | New |
| Jan 31, 2024 | Revenues | FY2024 | $15.70B – $16.30B | New |
| Nov 8, 2023 | CAPEX | FY2023 | $500.00M | Reaffirmed |
| Nov 8, 2023 | Adjusted EBITDA | FY2023 | $4.50B – $4.90B | Reaffirmed |
| Nov 8, 2023 | Non-GAAP diluted EPS | FY2023 | $2.25 – $2.55 | Reaffirmed |
| Nov 8, 2023 | Free cash flow | FY2023 | $1.70B – $2.10B | Reaffirmed |
| Nov 8, 2023 | Non-GAAP operating Income | FY2023 | $4.00B – $4.40B | Reaffirmed |
| Nov 8, 2023 | non-GAAP tax rate | FY2023 | 12% – 15% | Lowered |
| Nov 8, 2023 | revenues outlook | FY2023 | $15.10B – $15.50B | Raised |
| Aug 2, 2023 | CAPEX | FY2023 | $500.00M | Reaffirmed |
| Aug 2, 2023 | Adjusted EBITDA | FY2023 | $4.50B – $4.90B | Reaffirmed |
| Aug 2, 2023 | Non-GAAP diluted EPS | FY2023 | $2.25 – $2.55 | Reaffirmed |
| Aug 2, 2023 | Free cash flow | FY2023 | $1.70B – $2.10B | Reaffirmed |
| Aug 2, 2023 | Non-GAAP operating Income | FY2023 | $4.00B – $4.40B | Reaffirmed |
| Aug 2, 2023 | annual non-GAAP tax rate | FY2023 | 14% – 17% | Reaffirmed |
| Aug 2, 2023 | revenues | FY2023 | $15.00B – $15.40B | Raised |
| May 10, 2023 | Adjusted EBITDA | FY2023 | $4.50B – $4.90B | Reaffirmed |
| May 10, 2023 | Non-GAAP diluted EPS | FY2023 | $2.25 – $2.55 | Reaffirmed |
| May 10, 2023 | Free cash flow | FY2023 | $1.70B – $2.10B | Reaffirmed |
| May 10, 2023 | annual non-GAAP tax rate | FY2023 | 14% – 17% | Reaffirmed |
| May 10, 2023 | Revenues | FY2023 | $14.80B – $15.40B | New |
| Feb 8, 2023 | CAPEX | FY2023 | $500.00M | New |
| Feb 8, 2023 | Adjusted EBITDA | FY2023 | $4.50B – $4.90B | New |
| Feb 8, 2023 | Non-GAAP diluted EPS | FY2023 | $2.25 – $2.55 | New |
| Feb 8, 2023 | Free cash flow | FY2023 | $1.70B – $2.10B | New |
| Feb 8, 2023 | Operating Income | FY2023 | $4.00B – $4.40B | New |
| Feb 8, 2023 | Tax Rate | FY2023 | 14% – 17% | New |
| Feb 8, 2023 | Revenues | FY2023 | $14.80B – $15.40B | New |
| Nov 3, 2022 | CAPEX | FY2022 | $500.00M | New |
| Nov 3, 2022 | Adjusted EBITDA | FY2022 | $4.70B – $5.00B | Reaffirmed |
| Nov 3, 2022 | Non-GAAP diluted EPS | FY2022 | $2.40 – $2.60 | Reaffirmed |
| Nov 3, 2022 | Free cash flow | FY2022 | $1.90B – $2.20B | Reaffirmed |
| Nov 3, 2022 | Operating Income | FY2022 | $4.20B – $4.50B | Reaffirmed |
| Nov 3, 2022 | Non-GAAP tax rate | FY2022 | 12% – 14% | Lowered |
| Nov 3, 2022 | Revenues | FY2022 | $14.80B – $15.40B | New |
| Jul 26, 2022 | CAPEX | FY2022 | $500.00M | Lowered |
| Jul 26, 2022 | Adjusted EBITDA | FY2022 | $4.70B – $5.00B | Reaffirmed |
| Jul 26, 2022 | Non-GAAP diluted EPS | FY2022 | $2.40 – $2.60 | Reaffirmed |
| Jul 26, 2022 | Free cash flow | FY2022 | $1.90B – $2.20B | Reaffirmed |
| Jul 26, 2022 | Operating Income | FY2022 | $4.20B – $4.50B | Reaffirmed |
| Jul 26, 2022 | Non-GAAP tax rate | FY2022 | 13% – 14% | Lowered |
| Jul 26, 2022 | Revenues | FY2022 | $15.00B – $15.60B | Lowered |
| May 3, 2022 | CAPEX | FY2022 | $600.00M | Reaffirmed |
| May 3, 2022 | Adjusted EBITDA | FY2022 | $4.70B – $5.00B | Reaffirmed |
| May 3, 2022 | Non-GAAP diluted EPS | FY2022 | $2.40 – $2.60 | Reaffirmed |
| May 3, 2022 | Free cash flow | FY2022 | $1.90B – $2.20B | Reaffirmed |
| May 3, 2022 | Operating Income | FY2022 | $4.20B – $4.50B | Reaffirmed |
| May 3, 2022 | non-GAAP tax rate | FY2022 | 18% – 19% | Reaffirmed |
| May 3, 2022 | COPAXONE revenues | FY2022 | $750.00M | New |
| May 3, 2022 | Revenues | FY2022 | $15.40B – $16.00B | Lowered |
| Feb 9, 2022 | CAPEX | FY2022 | $600.00M | New |
| Feb 9, 2022 | EBITDA | FY2022 | $4.70B – $5.00B | New |
| Feb 9, 2022 | Non-GAAP diluted EPS | FY2022 | $2.40 – $2.60 | New |
| Feb 9, 2022 | Free cash flow | FY2022 | $1.90B – $2.20B | New |
| Feb 9, 2022 | Operating Income | FY2022 | $4.20B – $4.50B | New |
| Feb 9, 2022 | Non-GAAP Tax Rate | FY2022 | 18% – 19% | New |
| Feb 9, 2022 | Revenues | FY2022 | $15.60B – $16.20B | New |
| Oct 27, 2021 | Adjusted EBITDA | FY2021 | $4.80B – $5.10B | New |
| Oct 27, 2021 | EPS | FY2021 | $2.50 – $2.70 | New |
| Oct 27, 2021 | Free cash flow | FY2021 | $2.00B – $2.30B | New |
| Oct 27, 2021 | non-GAAP tax rate | FY2021 | 17% – 18% | New |
| Oct 27, 2021 | Net revenues | FY2021 | $16.00B – $16.40B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Teva Pharmaceutical Industries filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined ExecutionResults
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Update